title: Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma.
abstract: We previously reported that brentuximab vedotin (BV) enabled successful reduced-intensity allogeneic hematopoietic cell transplantation (RIC-alloHCT) in patients with relapsed Hodgkin lymphoma, after a median follow-up of 14.4 months. We now provide an updated report on 21 patients who were treated from 2009 to 2012 with BV before RIC-alloHCT with a uniform fludarabine/melphalan conditioning regimen and donor source after a median follow-up of 29.9 months. We have also retrospectively compared the patient characteristics and outcomes of these BV-pretreated patients to 23 patients who received fludarabine/melphalan RIC-alloHCT without prior BV, in the time period before the drug was available (2003 to 2009). Patients who were treated with BV before RIC-alloHCT had a lower median hematopoietic cell transplantation-specific comorbidity index and a reduced number of peri-transplantation toxicities. There were also improvements in 2-year progression-free survival (59.3% versus 26.1%) and cumulative incidence of relapse/progression (23.8% versus 56.5%).
authors.affiliation: Department of Hematology/Hematopoietic Cell Transplantation, City of Hope, Duarte, California. Electronic address: rchen@coh.org.
authors.forename: Robert
authors.initials: R
authors.lastname: Chen
authors.affiliation: Division of Biostatistics, City of Hope, Duarte, California.
authors.forename: Joycelynne M
authors.initials: JM
authors.lastname: Palmer
authors.affiliation: Division of Biostatistics, City of Hope, Duarte, California.
authors.forename: Ni-Chun
authors.initials: NC
authors.lastname: Tsai
authors.affiliation: Department of Hematology/Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
authors.forename: Sandra H
authors.initials: SH
authors.lastname: Thomas
authors.affiliation: Department of Hematology/Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
authors.forename: Tanya
authors.initials: T
authors.lastname: Siddiqi
authors.affiliation: Department of Hematology/Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
authors.forename: Leslie
authors.initials: L
authors.lastname: Popplewell
authors.affiliation: Bone Marrow Transplantation Program, City of Hope-Kaiser Permanente, Los Angeles, California.
authors.forename: Len
authors.initials: L
authors.lastname: Farol
authors.affiliation: Department of Hematology/Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
authors.forename: Auayporn
authors.initials: A
authors.lastname: Nademanee
authors.affiliation: Department of Hematology/Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Forman
mesh_terms: D000328:Adult; D000079963:Brentuximab Vedotin; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D019172:Transplantation Conditioning; D055815:Young Adult
chemical_list: D018796:Immunoconjugates; D000079963:Brentuximab Vedotin
keywords: Allogeneic transplantation; Brentuximab vedotin; Hodgkin lymphoma; Reduced-intensity